Peforelin

Peforelin
Clinical data
Trade names	Maprelin
Other names	Lamprey GnRH-III; H-Pyr-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2; XHWSHDWKPG
Routes of; administration	Injection
Drug class	GnRH agonist
Identifiers
	IUPAC name (3S)-4-[[(2S)-1-[[(2S)-6-amino-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoic acid;
CAS Number	147859-97-0;
PubChem CID	16197823;
ChemSpider	17326238;
UNII	UJ8NQ5Z0VX;
CompTox Dashboard (EPA)	DTXSID30163819 ;
ECHA InfoCard	100.223.356
Chemical and physical data
Formula	C59H74N18O14
Molar mass	1259.353 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O;
	InChI InChI=1S/C59H74N18O14/c60-16-6-5-12-40(59(91)77-17-7-13-47(77)58(90)66-27-48(61)79)70-52(84)41(18-31-23-64-37-10-3-1-8-35(31)37)72-56(88)45(22-50(81)82)75-55(87)44(21-34-26-63-30-68-34)74-57(89)46(28-78)76-53(85)42(19-32-24-65-38-11-4-2-9-36(32)38)71-54(86)43(20-33-25-62-29-67-33)73-51(83)39-14-15-49(80)69-39/h1-4,8-11,23-26,29-30,39-47,64-65,78H,5-7,12-22,27-28,60H2,(H2,61,79)(H,62,67)(H,63,68)(H,66,90)(H,69,80)(H,70,84)(H,71,86)(H,72,88)(H,73,83)(H,74,89)(H,75,87)(H,76,85)(H,81,82)/t39-,40-,41-,42-,43-,44-,45-,46-,47-/m0/s1; Key:RTASYRSYWSLWJV-CSYZDTNESA-N;

Peforelin (INNTooltip International Nonproprietary Name), or peforelin acetate, sold under the brand name Maprelin, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe and Canada.^[1]^[2]^[3]^[4] It is a GnRH analogue and a synthetic peptide, specifically a decapeptide.^[1]^[3]^[4] The drug was introduced for veterinary use by 2001.^[5]

References

^ ^a ^b "Archived copy". Archived from the original on 2019-08-29. Retrieved 2018-07-28.{{cite web}}: CS1 maint: archived copy as title (link)
^ "Maprelin XP-10 (Canada) for Animal Use".
^ ^a ^b Löscher W, Richter A, Potschka H (3 September 2014). Pharmakotherapie bei Haus- und Nutztieren: Begründet von W. Löscher, F.R. Ungemach und R. Kroker. Enke. pp. 435–. ISBN 978-3-8304-1251-9.
^ ^a ^b Rodriguez-Martinez H (1 April 2010). Control of Pig Reproduction VIII. Nottingham University Press. pp. 190–. ISBN 978-1-907284-53-3.
^ http://www.sgau.ru/files/pages/846/14713368000.pdf#page=48 ^{[bare URL PDF]}

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Drugs.com-1] "Archived copy". Archived from the original on 2019-08-29. Retrieved 2018-07-28.{{cite web}}: CS1 maint: archived copy as title (link)

[Drugs.com-Maprelin-XP10-2] "Maprelin XP-10 (Canada) for Animal Use".

[LöscherRichter2014-3] Löscher W, Richter A, Potschka H (3 September 2014). Pharmakotherapie bei Haus- und Nutztieren: Begründet von W. Löscher, F.R. Ungemach und R. Kroker. Enke. pp. 435–. ISBN 978-3-8304-1251-9.

[Rodriguez-Martinez2010-4] Rodriguez-Martinez H (1 April 2010). Control of Pig Reproduction VIII. Nottingham University Press. pp. 190–. ISBN 978-1-907284-53-3.

[Содержание2001-5] ttp://www.sgau.ru/files/pages/846/14713368000.pdf#page=48 ^{[bare URL PDF]}

[1]

[2]

[3]

[4]

[5]

See also

References